new glp-1 retatrutide 🚨 BREAKING: Shows “Bariatric-Level” Weight Loss in Phase 3 Trial Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most 💊🔥 Retatrutide: The Most Powerful
Description
Their expanding role beyond weight management and glycemic control presents new considerations for bone remodeling, perioperative risk reduction, and postoperative recovery in orthopedic surgery
Interestingly, when they used users of sulphonylureas as the comparator, GLP1-RAs users had a significant elevation in risk of thyroid cancer (weighted HR 1.80, 95% CI 1.282.52)
Do they have promise
Our study also showed GLP-1 agonists were associated with a lower risk of total stroke in patients without cardiovascular disease risk such as renal impairment, heart failure, or old age
doi:10.1152/ajpendo.2001.281.2.E197 Tipton KD, Gurkin BE, Matin S, Wolfe RR
